Table 1 Description of the patients (n = 753).

From: A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage

Patient characteristics

Value

Tumor characteristics

Value

Age, years

70 (63–76)

Kinki criteria

Gender

 B1

279

 Male

553

 B2

381

 Female

200

 B3

93

Etiology

TNM-LCSGJ

 HCV

516

 II

205

 HBV

71

 III

548

 HCV + HBV

15

Size of the largest nodules, cm

3 (1.9–4)

 nonBnonC

151

 < 1

2

ECOG, PS 0/1

753/0

 1–2

190

Total bilirubin, mg/dL

0.9 (0.6–1.3)

 2–3

168

AST, U/L

54 (37–75)

 3–4

179

ALT, U/L

41 (26.75–63)

 4–6

135

Albumin, g/dL

3.5 (3.1–3.9)

 6–10

63

Platelets, × 104/μL

10.1 (7.1–13.9)

 ≥ 10

16

Prothrombin time, %

85 (73.5–97.9)

Number of nodules

5 (3–7)

ALBI score

-2.22 (-2.59—-1.79)

 2

127

mALBI grade

 3

81

 1

184

 4

167

 2a

150

 5

95

 2b

355

 6–7

100

 3

64

 8–9

35

Child–Pugh score

 ≥ 10 or diffuse

148

 5

300

Naïve/recurrence

279/474

 6

242

AFP, ng/dL

39.6 (10.2–262.5)

 7

118

DCP, mAU/mL

111 (29–728.75)

 ≥ 8

93

  
  1. HCV hepatitis C virus, HBV hepatitis B virus, ECOG Eastern Cooperative Oncology Group, PS performance status, AST aspartate aminotransferase, ALT alanine aminotransferase, ALBI albumin-bilirubin, mALBI modified ALBI, TAE transcatheter arterial embolization, TACE transcatheter arterial chemoembolization, TKI tyrosine kinase inhibitor, TNM-LCSGJ tumor node metastasis-the liver cancer study group of Japan, AFP α-fetoprotein, DCP des-γ-carboxyprothrombin.